> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Positive Phase 1 Data on New Novo Weight-Loss Drug
- URL: https://www.fdaweb.com/positive-phase-1-data-on-new-novo-weight-loss-drug/
- Published: 2024-03-07T12:00:00.000Z
- Updated: 2026-09-14T14:24:50.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156502

Novo Nordisk says a Phase 1 trial of a pill version of its experimental weight-loss drug amycretin found that trial participants lost 13.1% of their weight after 12 weeks. Reuters [reports](https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-present-early-stage-trial-data-new-diabetes-drug-investor-meeting-2024-03-07/?ref=fdaweb.com) that the result compares to a 6% loss after 12 weeks and 15% after 68 weeks in trials for Novo Nordisk’s blockbuster Wegovy (semaglutide).

The news service says it also compares favorably to Lilly’s experimental orforglipron weight-loss pill, which achieved a 14.7% weight loss after 36 weeks in a mid-stage trial in people who were obese or overweight.